Skip to main content
Erschienen in: International Archives of Occupational and Environmental Health 3/2004

01.04.2004 | Original Article

Factors influencing long-term survival in mesothelioma patients—results of the German mesothelioma register

verfasst von: V. Neumann, A. Rütten, M. Scharmach, K.-M. Müller, M. Fischer

Erschienen in: International Archives of Occupational and Environmental Health | Ausgabe 3/2004

Einloggen, um Zugang zu erhalten

Abstract

Between 1987 and 2000, the German mesothelioma register recorded a total of 4,455 patients with malignant mesotheliomas. Survival times for 498 (11.2%) patients were available; 155 patients (study group, 3.5% of the total group) survived for more than 2 years and 343 patients (control group, 7.7% of the total group) survived for fewer than 24 months. Male patients were over-represented in both groups, with 13% of women in the study and 4.4% in the control group. The proportion of pleural mesotheliomas was more than 90% in both groups, with peritoneal cases comprising 6.5% in the study group and 3.2% in the control group. Histologically, the epithelioid subtype was represented in 58% of the study group, whereas the biphasic subtype predominated (67.6%) in the control group. Only 7% of tumours were of the sarcomatoid subtype. The average age of patients in the study group was 57.4 years, thus lower than in the control group (62.8 years). Lung dust analysis showed an increased pulmonary asbestos burden in 94% of all patients; significant differences between the study and control group were not observed. In the majority of the total group pleural effusions were the first symptoms. Therapeutic data were available in fewer than 40% of all cases. Surgical interventions were performed, partly in combination with radiation and chemotherapy and as alternative treatments. Significant deviations in survival time dependent on therapy applied could not be proved. By multivariate analysis (Cox proportional hazards regression model) favourable prognostic factors for long-term survival were epithelioid tumour subtype, comparatively young age (<60 years), and female gender (P<0.05).
Literatur
1.
Zurück zum Zitat Adams VI, Unni KK, Muhm JR, Jett JR, Ilstrup DM, Bernazt PE (1986) Diffuse malignant mesothelioma of the pleura. Diagnosis and survival in 92 cases. Cancer 58:1540–1551PubMed Adams VI, Unni KK, Muhm JR, Jett JR, Ilstrup DM, Bernazt PE (1986) Diffuse malignant mesothelioma of the pleura. Diagnosis and survival in 92 cases. Cancer 58:1540–1551PubMed
2.
Zurück zum Zitat Agudo A Gonzales C, Bleda M, Ramirez J, Hernandez S, Lopez F, Calleja A, Panades R, Turuguet D, Escolar A, Beltran M, Gonzales-Moya JE (2000) Occupation and risk of malignant pleural mesothelioma. A case control study in Spain. Am J Ind Med 37:159–168CrossRefPubMed Agudo A Gonzales C, Bleda M, Ramirez J, Hernandez S, Lopez F, Calleja A, Panades R, Turuguet D, Escolar A, Beltran M, Gonzales-Moya JE (2000) Occupation and risk of malignant pleural mesothelioma. A case control study in Spain. Am J Ind Med 37:159–168CrossRefPubMed
3.
Zurück zum Zitat Antmann KH (1993) Natural history and epidemiology of malignant mesothelioma. Chest 103[Supp]:373S–76S Antmann KH (1993) Natural history and epidemiology of malignant mesothelioma. Chest 103[Supp]:373S–76S
4.
Zurück zum Zitat Antmann KH, Shemin R, Ryan L (1988) Malignant mesothelioma: prognostic variables in a registry of 180 patients. The Dana Farber Institute and Brigham and Woman’s Hospital experience over two decades J Clin Oncol 6:147–153 Antmann KH, Shemin R, Ryan L (1988) Malignant mesothelioma: prognostic variables in a registry of 180 patients. The Dana Farber Institute and Brigham and Woman’s Hospital experience over two decades J Clin Oncol 6:147–153
5.
Zurück zum Zitat Attanoos R, Gibbs AR (1998) Peritoneal mesothelioma: clinicopathological analysis of 227 cases from the UK mesothelioma register. Clin Exp Pathol 46:376–376 Attanoos R, Gibbs AR (1998) Peritoneal mesothelioma: clinicopathological analysis of 227 cases from the UK mesothelioma register. Clin Exp Pathol 46:376–376
6.
Zurück zum Zitat Baas P (2002) Chemotherapy for malignant mesothelioma: from doxorubicin to vinorelbine. Semin Oncol 29:62–69CrossRef Baas P (2002) Chemotherapy for malignant mesothelioma: from doxorubicin to vinorelbine. Semin Oncol 29:62–69CrossRef
7.
Zurück zum Zitat Beer TW, Buchanan R, Mathews AW, Stradling R, Pullinger N, Pethybridge RJ (1998) Prognosis in malignant mesothelioma related to MIB 1 proliferation index and histological subtype. Hum Pathol 29:246–251PubMed Beer TW, Buchanan R, Mathews AW, Stradling R, Pullinger N, Pethybridge RJ (1998) Prognosis in malignant mesothelioma related to MIB 1 proliferation index and histological subtype. Hum Pathol 29:246–251PubMed
8.
Zurück zum Zitat Benard F, Sterman D, Smith RJ, Kaiser LR, Albelda SM, Alavi A (1999) Prognostic value of FDG PET imaging in malignant pleural mesothelioma. J Nucl Med 40:1241–1245 Benard F, Sterman D, Smith RJ, Kaiser LR, Albelda SM, Alavi A (1999) Prognostic value of FDG PET imaging in malignant pleural mesothelioma. J Nucl Med 40:1241–1245
9.
Zurück zum Zitat Bianchi C, Giarelli L, Grandi G, Brollo A, Ramani L, Zuch C (1997) Latency periods in asbestos related mesothelioma of the pleura. Eur J Cancer Prev 6:162–166 Bianchi C, Giarelli L, Grandi G, Brollo A, Ramani L, Zuch C (1997) Latency periods in asbestos related mesothelioma of the pleura. Eur J Cancer Prev 6:162–166
10.
Zurück zum Zitat Bischoff HG, Manegold C, Drings P (2000) Langzeit-Spontanverlauf beim malignen Pleuramesotheliom. Pneumologie 54:S31 Bischoff HG, Manegold C, Drings P (2000) Langzeit-Spontanverlauf beim malignen Pleuramesotheliom. Pneumologie 54:S31
11.
Zurück zum Zitat Blecklake MR (1976) Asbestos related diseases of the lung and other organs: their epidemiology and implications for clinical practice. Am J Respir Dis 114:187–227 Blecklake MR (1976) Asbestos related diseases of the lung and other organs: their epidemiology and implications for clinical practice. Am J Respir Dis 114:187–227
12.
Zurück zum Zitat Brenner J, Sordillo PP, Magill MG, Golbey RB (1981) Malignant peritoneal mesothelioma: review of 25 patients. Am J Gastroenterol 75:311–313PubMed Brenner J, Sordillo PP, Magill MG, Golbey RB (1981) Malignant peritoneal mesothelioma: review of 25 patients. Am J Gastroenterol 75:311–313PubMed
13.
Zurück zum Zitat Brenner J, Sordillo PP, Magil GB, Golgey RB (1982) Malignant mesothelioma of the pleura. Cancer 49:2431–2435PubMed Brenner J, Sordillo PP, Magil GB, Golgey RB (1982) Malignant mesothelioma of the pleura. Cancer 49:2431–2435PubMed
14.
Zurück zum Zitat Brockmann M, Fischer M, Müller KM (1989) Lungenstaubanalyse bei Bronchialkarzinomen. Atemw Lungenkrkh 15:263–265 Brockmann M, Fischer M, Müller KM (1989) Lungenstaubanalyse bei Bronchialkarzinomen. Atemw Lungenkrkh 15:263–265
15.
Zurück zum Zitat Browne K, Smither WJ (1983) Asbestos related mesothelioma: factors discriminating between pleural and peritoneal sites. Br J Ind Med 40:145–152PubMed Browne K, Smither WJ (1983) Asbestos related mesothelioma: factors discriminating between pleural and peritoneal sites. Br J Ind Med 40:145–152PubMed
16.
Zurück zum Zitat Chahinian APH, Pajak TF, Holland JF, Norton L, Armbinder RM, Mandel EM (1982) Diffuse malignant mesothelioma (prospective evaluation of 69 patients) Ann Intern Med 96:746–755 Chahinian APH, Pajak TF, Holland JF, Norton L, Armbinder RM, Mandel EM (1982) Diffuse malignant mesothelioma (prospective evaluation of 69 patients) Ann Intern Med 96:746–755
17.
Zurück zum Zitat Chailleux E, Dabouis G, Pioche D, deLajarte M, deLajarte AY, Rembeaux A, Germaud P (1988) Prognostic factors in diffuse malignant pleural mesothelioma. Chest 93:159–162PubMed Chailleux E, Dabouis G, Pioche D, deLajarte M, deLajarte AY, Rembeaux A, Germaud P (1988) Prognostic factors in diffuse malignant pleural mesothelioma. Chest 93:159–162PubMed
18.
Zurück zum Zitat Craighead JE (1982) Asbestos related diseases. Arch Pathol Lab Med 106:544–596PubMed Craighead JE (1982) Asbestos related diseases. Arch Pathol Lab Med 106:544–596PubMed
19.
Zurück zum Zitat Dienemman H, Trainer C (2000) Mesotheliom der Pleura und des Peritoneums. Chirurg 71:887–893CrossRefPubMed Dienemman H, Trainer C (2000) Mesotheliom der Pleura und des Peritoneums. Chirurg 71:887–893CrossRefPubMed
20.
Zurück zum Zitat Edwards JG, Abrams KR, Leverment JN, Spyt TJ, Waller DA, O’Byrne KJ (2000) Prognostic factors for malignant mesothelioma in 142 patients: validation of CALGB and EORTC prognosis scoring systems. Thorax 55:731–735CrossRefPubMed Edwards JG, Abrams KR, Leverment JN, Spyt TJ, Waller DA, O’Byrne KJ (2000) Prognostic factors for malignant mesothelioma in 142 patients: validation of CALGB and EORTC prognosis scoring systems. Thorax 55:731–735CrossRefPubMed
21.
Zurück zum Zitat Ehlers EM, Kühnel W, Wiedemann GJ (2002) Hyperthermia and mafosfamide in a human derived malignant pleural mesothelioma cell line. J Cancer Res Clin Oncol 128:65–72CrossRefPubMed Ehlers EM, Kühnel W, Wiedemann GJ (2002) Hyperthermia and mafosfamide in a human derived malignant pleural mesothelioma cell line. J Cancer Res Clin Oncol 128:65–72CrossRefPubMed
22.
Zurück zum Zitat Elmes PC, Simpson JC (1976) The clinical aspects of mesothelioma. Q J Med 45:427–449PubMed Elmes PC, Simpson JC (1976) The clinical aspects of mesothelioma. Q J Med 45:427–449PubMed
23.
Zurück zum Zitat Fizazi K, John WJ, Vogelzang NJ (2002) The emerging role of antifolates in the treatment of malignant mesothelioma. Semin Oncol 1:77–81CrossRef Fizazi K, John WJ, Vogelzang NJ (2002) The emerging role of antifolates in the treatment of malignant mesothelioma. Semin Oncol 1:77–81CrossRef
24.
Zurück zum Zitat Frizelle SP, Rubins JB, Zhou JX (2000) Gene therapy of established mesothelioma xenograft with recombinant p16INK4a adenovirus. Cancer Gene Ther 7:1421–1425CrossRefPubMed Frizelle SP, Rubins JB, Zhou JX (2000) Gene therapy of established mesothelioma xenograft with recombinant p16INK4a adenovirus. Cancer Gene Ther 7:1421–1425CrossRefPubMed
25.
Zurück zum Zitat Girling DJ, Muers MF, Qian W, Lobban D (2002) Multicentre randomised controlled trial of the management of unresectable malignant mesothelioma proposed by the British Thoracic Society Medical Research Council. Semin Oncol 29:97–101CrossRefPubMed Girling DJ, Muers MF, Qian W, Lobban D (2002) Multicentre randomised controlled trial of the management of unresectable malignant mesothelioma proposed by the British Thoracic Society Medical Research Council. Semin Oncol 29:97–101CrossRefPubMed
26.
Zurück zum Zitat Grondin C, Sugarbaker DJ (1999) Malignant mesothelioma of the pleural space. Oncology 13:919–26PubMed Grondin C, Sugarbaker DJ (1999) Malignant mesothelioma of the pleural space. Oncology 13:919–26PubMed
27.
Zurück zum Zitat Hillerdal G (1983) Malignant mesothelioma. Review of 4710 published cases. Br J Dis Chest 77:321–343PubMed Hillerdal G (1983) Malignant mesothelioma. Review of 4710 published cases. Br J Dis Chest 77:321–343PubMed
28.
Zurück zum Zitat Howel D, Arblaster L, Swinburne L, Schweiger M, Renvoize E, Hatton P (1997) Routes of asbestos exposure and the development of mesothelioma in an English region. Occup Environ Med 54:403–409PubMed Howel D, Arblaster L, Swinburne L, Schweiger M, Renvoize E, Hatton P (1997) Routes of asbestos exposure and the development of mesothelioma in an English region. Occup Environ Med 54:403–409PubMed
29.
Zurück zum Zitat Jaklitsch MT Grondin SC, Sugarbaker DJ (2001) Treatment of malignant mesothelioma. World J Surg 25:210–217CrossRefPubMed Jaklitsch MT Grondin SC, Sugarbaker DJ (2001) Treatment of malignant mesothelioma. World J Surg 25:210–217CrossRefPubMed
30.
Zurück zum Zitat Kjaergaard J, Andersson M (2000) Incidence rates of malignant mesothelioma in Denmark predicted future number of cases among men. Scand J Work Environ Health 26:112–117PubMed Kjaergaard J, Andersson M (2000) Incidence rates of malignant mesothelioma in Denmark predicted future number of cases among men. Scand J Work Environ Health 26:112–117PubMed
31.
Zurück zum Zitat Kramer G, Gans S, Rijnders A, Leer JW (2000) Long term survival of a patient with malignant pleural mesothelioma as a late complication of radiotherapy for Hodgkin’s disease with90yttrium-silicate. Lung Cancer 27:205–208CrossRefPubMed Kramer G, Gans S, Rijnders A, Leer JW (2000) Long term survival of a patient with malignant pleural mesothelioma as a late complication of radiotherapy for Hodgkin’s disease with90yttrium-silicate. Lung Cancer 27:205–208CrossRefPubMed
32.
Zurück zum Zitat Kucharczuk JC, Kaiser LR (1997) Use of a replication restricted herpes virus to treat experimental human malignant mesothelioma. Cancer Res 57:466–471PubMed Kucharczuk JC, Kaiser LR (1997) Use of a replication restricted herpes virus to treat experimental human malignant mesothelioma. Cancer Res 57:466–471PubMed
33.
Zurück zum Zitat Lanphear BP, Buncher RC (1992) Latent period for malignant mesothelioma of occupational origin. J Occup Med 34:718PubMed Lanphear BP, Buncher RC (1992) Latent period for malignant mesothelioma of occupational origin. J Occup Med 34:718PubMed
34.
Zurück zum Zitat Livitra EJ, Vyas V, Nelson K, Musanti R, Beers St, Thomas C, Poplin E, Smith S, Lin Y, Schaaf LJ, Aisner J, Gounder M, Rajendra R, Saleem A, Toppmeyer D, Rubin EH (2003) Phase I evaluation of sequential topoisomerase targeting with irinotecan/cisplatin followed by etoposide in patients with advanced malignancy. Clin Cancer Res 9:1673–1679PubMed Livitra EJ, Vyas V, Nelson K, Musanti R, Beers St, Thomas C, Poplin E, Smith S, Lin Y, Schaaf LJ, Aisner J, Gounder M, Rajendra R, Saleem A, Toppmeyer D, Rubin EH (2003) Phase I evaluation of sequential topoisomerase targeting with irinotecan/cisplatin followed by etoposide in patients with advanced malignancy. Clin Cancer Res 9:1673–1679PubMed
35.
Zurück zum Zitat McDonald AD, McDonald JC (1980) Malignant mesothelioma in North America. Cancer 46:1650–1656PubMed McDonald AD, McDonald JC (1980) Malignant mesothelioma in North America. Cancer 46:1650–1656PubMed
36.
Zurück zum Zitat Middleton GW, Smith IE, O’Brian MER (1998) Good symptom relief with palliative MVP (mitomycin-C, vinblastine and cisplatin) chemotherapy in malignant mesothelioma. Ann Oncol 9:269–273CrossRefPubMed Middleton GW, Smith IE, O’Brian MER (1998) Good symptom relief with palliative MVP (mitomycin-C, vinblastine and cisplatin) chemotherapy in malignant mesothelioma. Ann Oncol 9:269–273CrossRefPubMed
37.
Zurück zum Zitat Müller KM (1997) Mesotheliome: Pathologie/Pathogenese/Mesotheliomregister. Pneumologie 51:335–344PubMed Müller KM (1997) Mesotheliome: Pathologie/Pathogenese/Mesotheliomregister. Pneumologie 51:335–344PubMed
38.
Zurück zum Zitat Neumann V, Müller KM, Fischer M (1999) Peritoneale Mesotheliome—Häufigkeiten und Ätiologie. Pathologe 20:169–176PubMed Neumann V, Müller KM, Fischer M (1999) Peritoneale Mesotheliome—Häufigkeiten und Ätiologie. Pathologe 20:169–176PubMed
39.
Zurück zum Zitat Neumann V, Günther S, Müller KM, Fischer M (2001) Malignant mesothelioma—German mesothelioma register 1987 to 1999. Int Arch Occup Environ Health 74:383–395CrossRefPubMed Neumann V, Günther S, Müller KM, Fischer M (2001) Malignant mesothelioma—German mesothelioma register 1987 to 1999. Int Arch Occup Environ Health 74:383–395CrossRefPubMed
40.
Zurück zum Zitat Ng DC, Hain SF, O’Doherty MJ, Dussek J (2000) Prognostic value of FDG PET imaging in malignant pleural mesothelioma. J Nucl Med 41:1443–1444 Ng DC, Hain SF, O’Doherty MJ, Dussek J (2000) Prognostic value of FDG PET imaging in malignant pleural mesothelioma. J Nucl Med 41:1443–1444
41.
Zurück zum Zitat Otto H (1980) Das berufsbedingte Mesotheliom in der BRD. Pathologe 2:8–18PubMed Otto H (1980) Das berufsbedingte Mesotheliom in der BRD. Pathologe 2:8–18PubMed
42.
Zurück zum Zitat Peto J, Decarli A, LaVecchia C, Levi F, Negri E (1999) The European mesothelioma epidemic. Br J Cancer 79:666–672CrossRefPubMed Peto J, Decarli A, LaVecchia C, Levi F, Negri E (1999) The European mesothelioma epidemic. Br J Cancer 79:666–672CrossRefPubMed
43.
Zurück zum Zitat Rieck G, Neumann V, Müller KM, Fischer M (2002) Lange Überlebenszeiten bei Patienten mit malignen Mesotheliomen—Gibt es einen Bezug zur histologischen Subtypisierung? Atemw Lungenkrkh 28:371–372 Rieck G, Neumann V, Müller KM, Fischer M (2002) Lange Überlebenszeiten bei Patienten mit malignen Mesotheliomen—Gibt es einen Bezug zur histologischen Subtypisierung? Atemw Lungenkrkh 28:371–372
44.
Zurück zum Zitat Robinson B (2002) Biology and gene therapy of malignant mesothelioma. Second Heidelberg thoracic oncology symposium: diagnosis and treatment of pleural mesothelioma in Heidelberg, limited handout, German Thoraxklinik, Heidelberg, Germany Robinson B (2002) Biology and gene therapy of malignant mesothelioma. Second Heidelberg thoracic oncology symposium: diagnosis and treatment of pleural mesothelioma in Heidelberg, limited handout, German Thoraxklinik, Heidelberg, Germany
45.
Zurück zum Zitat Roggli VL, Oury TD, Moffatt EJ (1997) Malignant mesothelioma in women. In: Fechner RE, Rosen PP (eds) Anatomic pathology, vol 2. ASCP Press, pp 147–163 Roggli VL, Oury TD, Moffatt EJ (1997) Malignant mesothelioma in women. In: Fechner RE, Rosen PP (eds) Anatomic pathology, vol 2. ASCP Press, pp 147–163
46.
Zurück zum Zitat Ruffie P, Feld R, Minkin S (1989) Diffuse malignant mesothelioma of the pleura in Ontario and Quebec, a retroprospective study of 332 patients. J Clin Oncol 8:1157–1168 Ruffie P, Feld R, Minkin S (1989) Diffuse malignant mesothelioma of the pleura in Ontario and Quebec, a retroprospective study of 332 patients. J Clin Oncol 8:1157–1168
47.
Zurück zum Zitat Rusch VW, Venkatraman E (1999) Important prognostic factors in patients with malignant pleural mesothelioma, managed surgically. Ann Thorac Surg 68:1799–1802CrossRefPubMed Rusch VW, Venkatraman E (1999) Important prognostic factors in patients with malignant pleural mesothelioma, managed surgically. Ann Thorac Surg 68:1799–1802CrossRefPubMed
48.
Zurück zum Zitat Ryan CW, Herndorn J, Vogelzang NJ (1998) A review of chemotherapy trials for malignant mesothelioma. Chest 113:66S–73SPubMed Ryan CW, Herndorn J, Vogelzang NJ (1998) A review of chemotherapy trials for malignant mesothelioma. Chest 113:66S–73SPubMed
49.
Zurück zum Zitat Smythe WR (2002) Current therapy for malignant mesothelioma Curr Oncol Rep 4:305–313 Smythe WR (2002) Current therapy for malignant mesothelioma Curr Oncol Rep 4:305–313
50.
Zurück zum Zitat Steele JPC, Shamasch J, Evans MT (2000) Phase II study of vinorelbine in patients with malignant pleural mesothelioma. J Clin Oncol 18:3912–3917PubMed Steele JPC, Shamasch J, Evans MT (2000) Phase II study of vinorelbine in patients with malignant pleural mesothelioma. J Clin Oncol 18:3912–3917PubMed
51.
Zurück zum Zitat Sterman DH, Treat J, Kaiser LR (1998) Adenovirus mediated herpes simplex virus thymidine kinase ganciclovir gene therapy in patients with localized malignancy: results of a phase I clinical trial in malignant mesothelioma. Hum Gene Ther 9:1083–1092 Sterman DH, Treat J, Kaiser LR (1998) Adenovirus mediated herpes simplex virus thymidine kinase ganciclovir gene therapy in patients with localized malignancy: results of a phase I clinical trial in malignant mesothelioma. Hum Gene Ther 9:1083–1092
52.
Zurück zum Zitat Strizzi L, Muaro R, Vianale G, Natoli C, Talone L, Catalano A, Mutti L, Tassi G, Procopio A (2002) Expression of glycoprotein 90 k in human malignant mesothelioma: correlation with patient survival. J Pathol 197:218–223CrossRefPubMed Strizzi L, Muaro R, Vianale G, Natoli C, Talone L, Catalano A, Mutti L, Tassi G, Procopio A (2002) Expression of glycoprotein 90 k in human malignant mesothelioma: correlation with patient survival. J Pathol 197:218–223CrossRefPubMed
53.
Zurück zum Zitat Sugarbaker DJ, Flores RM, Jaklitsch MT, Richards WG, Strauss GM, Corson JM, DeCamp, Swanson MM, Bueno R, Lukanich JM, Baldini EH, Mentzer SJ (1999) Resection margins, extrapleural nodal status, and cell type determine postoperative long term survival in trimodality therapy of malignant pleural mesothelioma: results in 183 patients. J Thorac Cardiovasc Surg 117:54–65PubMed Sugarbaker DJ, Flores RM, Jaklitsch MT, Richards WG, Strauss GM, Corson JM, DeCamp, Swanson MM, Bueno R, Lukanich JM, Baldini EH, Mentzer SJ (1999) Resection margins, extrapleural nodal status, and cell type determine postoperative long term survival in trimodality therapy of malignant pleural mesothelioma: results in 183 patients. J Thorac Cardiovasc Surg 117:54–65PubMed
54.
Zurück zum Zitat Vogelzang NJ, Rusthoven JJ, Symanowski J, Denham C, Kaukel E, Ruffie P, Gatzmeier U, Boyer M, Emri S, Manegold C, Niykiza C, Paoletti P (2003) Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol 15:2636–2644CrossRef Vogelzang NJ, Rusthoven JJ, Symanowski J, Denham C, Kaukel E, Ruffie P, Gatzmeier U, Boyer M, Emri S, Manegold C, Niykiza C, Paoletti P (2003) Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol 15:2636–2644CrossRef
55.
Zurück zum Zitat Wächli I, Rajower I, Christens B, Mirza S, Rüttner JR (1988) Ferruginous Bodies im Lungenstaub als Indikatoren für Asbestschäden. Pathologe 8:346–350 Wächli I, Rajower I, Christens B, Mirza S, Rüttner JR (1988) Ferruginous Bodies im Lungenstaub als Indikatoren für Asbestschäden. Pathologe 8:346–350
56.
Zurück zum Zitat Wagner JC, Sleggs CA, Marchand P (1960) Diffuse pleural mesothelioma and asbestos exposure in the North Western Cape Province. Brit J Ind Med 17:260–271 Wagner JC, Sleggs CA, Marchand P (1960) Diffuse pleural mesothelioma and asbestos exposure in the North Western Cape Province. Brit J Ind Med 17:260–271
57.
Zurück zum Zitat Warren WH (2000) Malignancies involving the pericardium. Semin Thorac Cardiovasc Surg 12:119–129PubMed Warren WH (2000) Malignancies involving the pericardium. Semin Thorac Cardiovasc Surg 12:119–129PubMed
58.
Zurück zum Zitat Woitowitz HJ, Grossgarten K (1991) Pleuramesotheliom: Ätiologie und praktische Konsequenzen. Pneumologie 45:153–158PubMed Woitowitz HJ, Grossgarten K (1991) Pleuramesotheliom: Ätiologie und praktische Konsequenzen. Pneumologie 45:153–158PubMed
59.
Zurück zum Zitat Yates DH, Corrin B, Stidolph PN, Browne K (1997) Malignant mesothelioma in South East England: clinicopathological experience of 272 cases. Thorax 52:507–512PubMed Yates DH, Corrin B, Stidolph PN, Browne K (1997) Malignant mesothelioma in South East England: clinicopathological experience of 272 cases. Thorax 52:507–512PubMed
60.
Zurück zum Zitat Zellos LS, Sugarbaker DJ (2002) Diffuse malignant mesothelioma of the pleural space and its management. Oncology 16:907–913PubMed Zellos LS, Sugarbaker DJ (2002) Diffuse malignant mesothelioma of the pleural space and its management. Oncology 16:907–913PubMed
Metadaten
Titel
Factors influencing long-term survival in mesothelioma patients—results of the German mesothelioma register
verfasst von
V. Neumann
A. Rütten
M. Scharmach
K.-M. Müller
M. Fischer
Publikationsdatum
01.04.2004
Verlag
Springer-Verlag
Erschienen in
International Archives of Occupational and Environmental Health / Ausgabe 3/2004
Print ISSN: 0340-0131
Elektronische ISSN: 1432-1246
DOI
https://doi.org/10.1007/s00420-003-0498-6

Weitere Artikel der Ausgabe 3/2004

International Archives of Occupational and Environmental Health 3/2004 Zur Ausgabe